Regeneron Pharmaceuticals (REGN) stock surged 5.05% in intraday trading, defying expectations after reporting first-quarter 2025 earnings that fell short of analyst estimates. The biotechnology company posted adjusted earnings per share of $8.22, missing the Zacks Consensus Estimate of $8.43.
Despite the earnings miss, investor sentiment remains bullish, driven by a flurry of analyst actions. While some firms adjusted their price targets downward, many maintained positive ratings on the stock. Notably, Truist Securities maintained a Buy rating with a price target of $940, Goldman Sachs kept its Buy rating, and Wells Fargo reiterated an Overweight rating. These actions suggest that analysts see strong potential in Regeneron's pipeline and market position, outweighing short-term earnings concerns.
The stock's impressive performance placed Regeneron among the top performers in both the S&P 500 and Nasdaq 100 indices for the day. This surge indicates that investors are focusing on the company's long-term prospects rather than quarterly fluctuations, highlighting the resilience and perceived value of Regeneron in the competitive biotech landscape.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。